Developing a maternal vaccine against Group B Streptococcus


At a glance

At a glance
Year of investment: 2022
Sector: Vaccines
Stage: Clinical development
Headquarters: Denmark
CEO: Per Fischer
Trill Impact board representative: Bita Sehat


Business description

MinervaX is a Danish biotech company developing a maternal vaccine to prevent life-threatening infections in newborns. The vaccine seeks to avoid Group B streptococcus (“GBS”) bacteria responsible for infant deaths, stillbirths, and severe disabilities in children globally. 

MinervaX's solution

TI (115)

Social/Environmental challenge

GBS bacteria the leading cause of life-threatening bacterial infection in newborns, causing infant mortality and stillbirth as well as severe pregnancy complications for the mother

Disproportionately affects low- and middle-income countries

Increasing AMR: Prophylactic antibiotics treatment offered to women at risk, driving antimicrobial resistance


SDG Contribution

SDG #3.1 – Reduce maternal mortality 
Potential contribution: Reduce preventable deaths caused by GBS infection in pregnant mothers

SDG # 3.2: End all preventable deaths under 5 years of age 
Potential contribution: Reduce preventable deaths caused by GBS infection in newborns

SDG #3.3 – Fighting communicable diseases
Potential contribution: Reduction of GBS infections and combating antimicrobial resistance

SDG #3.b – support R&D, and universal access to affordable vaccines and medicines
Potential contribution: Affordable vaccine that allows for global distribution through established procurement and distribution mechanisms

This website uses cookiesfor statistics and user experience.

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read ours privacy policy. If you agree to our use, choose Accept all. If you want to change your choice afterwards, you will find that option at the bottom of the page.